Onconetix, Inc. — Form 8-K
Filed July 29, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 92/100
What the filing says
Onconetix authorized and issued 37,812 Series F Convertible Preferred Stock shares at $1,000 stated value per share (aggregate ~$37.8M) to unnamed investors on July 28, 2026. Shares convert to common stock at $0.9767 floor price, with 125% redemption premium and 15% default dividend rate if triggering events occur. Company must reserve 150% of conversion shares and faces strict covenants on debt, liens, and asset transfers.
Why this rating
At ~$3.6M market cap, a $37.8M preferred issuance is 10.5x company size—transformational dilution. Heavy conversion mechanics, default provisions, and operational restrictions pose material going-concern risk.
See more from July 29, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.